Literature DB >> 19707509

Complete remission in a patient with human herpes virus-8 negative multicentric Castleman disease using CHOP chemotherapy.

Hee Yeon Seo1, Eui Bae Kim, Jee Won Kim, Bong Kyoung Shin, Seok Jin Kim, Byung Soo Kim.   

Abstract

Multicentric Castleman disease (MCD) is a rare lymphoproliferative disorder. Although MCD pathogenesis is unclear, studies have suggested that human herpesvirus 8 (HHV-8) may be associated with the disorder. Recent reports have identified MCD cases without viral infection. A 43-year-old woman presented to our hospital for fever and myalgia of 6 months' duration. The complete blood count revealed an elevated leukocyte count (15.1x10(3)/microL) and a decreased hemoglobin level of 10.0 g/dL. The C-reactive protein level was elevated at 276.5 mg/L. Thoracic computed tomography (CT) scans revealed bilateral axillary lymphadenopathy. There was no evidence of HHV-8, human immunodeficiency virus (HIV), or Mycobacterium infection. Histologic evaluation of a lymph node biopsy from the left axilla yielded a diagnosis of MCD. Cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) were administered for a total of 4 cycles. The patient's fever and lymphadenopathy resolved after the course of chemotherapy. She has been in complete remission for 24 months at this writing. As previously reported, this case report suggests that MCD can develop without viral infection. CHOP chemotherapy may be an effective treatment option for newly diagnosed MCD patients.

Entities:  

Keywords:  Chemotherapy; Human herpes virus 8; Multicentric Castleman disease

Year:  2009        PMID: 19707509      PMCID: PMC2731214          DOI: 10.4143/crt.2009.41.2.104

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN: 1598-2998            Impact factor:   4.679


  15 in total

1.  Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6.

Authors:  Y Aoki; E S Jaffe; Y Chang; K Jones; J Teruya-Feldstein; P S Moore; G Tosato
Journal:  Blood       Date:  1999-06-15       Impact factor: 22.113

2.  Localized mediastinal lymphnode hyperplasia resembling thymoma.

Authors:  B CASTLEMAN; L IVERSON; V P MENENDEZ
Journal:  Cancer       Date:  1956 Jul-Aug       Impact factor: 6.860

3.  Expression of ICAM-1, VCAM-1 and ELAM-1 in angiofollicular lymph node hyperplasia (Castleman's disease): evidence for dysplasia of follicular dendritic reticulum cells.

Authors:  L P Ruco; A J Gearing; R Pigott; D Pomponi; V L Burgio; A Cafolla; A Baiocchini; C D Baroni
Journal:  Histopathology       Date:  1991-12       Impact factor: 5.087

4.  Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations.

Authors:  A R Keller; L Hochholzer; B Castleman
Journal:  Cancer       Date:  1972-03       Impact factor: 6.860

5.  A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients.

Authors:  G Frizzera; P M Banks; G Massarelli; J Rosai
Journal:  Am J Surg Pathol       Date:  1983-04       Impact factor: 6.394

6.  A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients.

Authors:  G Frizzera; B A Peterson; E D Bayrd; A Goldman
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

7.  Retinoic acid for treatment of multicentric Castleman's disease.

Authors:  P Rieu; D Droz; A Gessain; J P Grünfeld; O Hermine
Journal:  Lancet       Date:  1999-10-09       Impact factor: 79.321

8.  Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab.

Authors:  Makoto Ide; Yasunori Kawachi; Yoichiro Izumi; Kanji Kasagi; Tetsuro Ogino
Journal:  Eur J Haematol       Date:  2006-02       Impact factor: 2.997

9.  Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.

Authors:  Y Chang; E Cesarman; M S Pessin; F Lee; J Culpepper; D M Knowles; P S Moore
Journal:  Science       Date:  1994-12-16       Impact factor: 47.728

10.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease.

Authors:  J Soulier; L Grollet; E Oksenhendler; P Cacoub; D Cazals-Hatem; P Babinet; M F d'Agay; J P Clauvel; M Raphael; L Degos
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113

View more
  7 in total

1.  Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman's disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately.

Authors:  Xuan Lan; Zhaoming Li; Mingzhi Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-07       Impact factor: 4.553

2.  Sustained remission of severe Multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance.

Authors:  Lucie M Turcotte; Colleen K Correll; Robyn C Reed; Christopher L Moertel
Journal:  Pediatr Blood Cancer       Date:  2013-09-09       Impact factor: 3.167

3.  Clinicopathological Profile of Castleman's Disease in Indian Population: Experience From a Tertiary Care Center.

Authors:  Ashok Singh; Suvendu Purkait; Saumyaranjan Mallick; Prashant Ramteke; Chandan Krushna Das; Ajay Gogia; Maher Chand Sharma; Lalit Kumar
Journal:  Indian J Hematol Blood Transfus       Date:  2019-09-25       Impact factor: 0.900

4.  Castleman's disease imitating adrenal mass in the retroperitoneal area.

Authors:  Gökhan Koç; Hakan Turk; Sıtkı Un; Cemal Selcuk Isoglu; Ferruh Zorlu
Journal:  Can Urol Assoc J       Date:  2015 Jan-Feb       Impact factor: 1.862

Review 5.  Castleman's disease: from basic mechanisms to molecular therapeutics.

Authors:  Hazem E El-Osta; Razelle Kurzrock
Journal:  Oncologist       Date:  2011-03-25

6.  Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.

Authors:  Li Yu; Meifeng Tu; Jorge Cortes; Zijun Y Xu-Monette; Roberto N Miranda; Jun Zhang; Robert Z Orlowski; Sattva Neelapu; Prajwal C Boddu; Mary A Akosile; Thomas S Uldrick; Robert Yarchoan; L Jeffrey Medeiros; Yong Li; David C Fajgenbaum; Ken H Young
Journal:  Blood       Date:  2017-01-18       Impact factor: 22.113

Review 7.  Multicentric Castleman's disease: a challenging diagnosis.

Authors:  Györgyi Műzes; Ferenc Sipos; Judit Csomor; Lídia Sréter
Journal:  Pathol Oncol Res       Date:  2013-03-21       Impact factor: 3.201

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.